Citable filing context

IFF filing events and research context

Server-rendered

IFF's research view summarizes recent SEC filing context, starting with business from Feb 27, 2026.

IFF filing events and research context
FiledItemContext
Feb 27, 2026businessInternational Flavors & Fragrances Inc. (IFF) is a global leader in the creation and manufacture of scents, tastes, and bioscience products serving the Food & Beverage, Home & Personal Care, and Health & Wellness markets. The company operates through five reportable segments: Taste, Food Ingredients, Health & Biosciences, Scent, and Pharma Solutions. Key product categories include enzymes, probiotics, soy proteins, and fragrance compounds. IFF is currently executing a strategic portfolio optimization, highlighted by the divestiture of its Pharma Solutions business for approximately $2.6 billion and the sale of its Cosmetic Ingredients business. To improve operational efficiency, the company is implementing a productivity program expected to cost between $110 million and $130 million through 2026. Financial risks are highlighted by significant goodwill impairments, including a $1.153 billion charge recognized in the Food Ingredients reporting unit in 2025. Additionally, the company faces ongoing regulatory investigations within its fragrance businesses. IFF recently reorganized its internal structure, splitting the former Nourish segment into separate Taste and Food Ingredients segments to better align resources and assess performance.
Feb 27, 2026mdaIFF reorganized its operations in 2025 into Taste, Food Ingredients, Health & Biosciences, and Scent, following the May 2025 divestiture of Pharma Solutions. Reported 2025 sales decreased 5% to $10.89 billion, though comparable currency-neutral sales grew 2%. A significant financial impact was a $1.153 billion goodwill impairment charge recorded for the Food Ingredients reporting unit. Segment performance was mixed: Taste and Health & Biosciences grew through volume and pricing in Food Biosciences and Grain Processing, while Food Ingredients declined 3% due to volume losses in Protein Solutions and the strategic exit of low-margin business. Scent growth was driven by Fragrance Compounds, which offset declines in Fragrance Ingredients. IFF focused on debt reduction, utilizing divestiture proceeds to repurchase $2 billion in Senior Notes, resulting in a net debt to credit adjusted EBITDA ratio of 2.59x. Operating cash flow fell to $850 million, impacted by higher working capital and incentive payouts. The company maintains significant customer concentration, with its 25 largest multinational clients accounting for 32% of total sales. Future capital spending for 2026 is projected at approximately 6% of sales.
Feb 27, 2026risk_factorsIFF is exposed to shifting consumer preferences driven by health awareness and the rise of weight-management pharmaceuticals, alongside a broader trend toward clean labels. The company faces intense competition as it expands into lower-margin functional foods and specialty fine ingredients. Financial stability is pressured by $5.994 billion in total debt, which prompted a 50% dividend reduction to prioritize deleveraging. Significant asset risk exists with $14.3 billion in goodwill and intangible assets, evidenced by a recent $1.153 billion impairment charge in the Food Ingredients segment. Legal headwinds include ongoing antitrust investigations and class action lawsuits in the U.S. and Canada. Regulatory challenges include the European Commission’s microplastics ban and restrictive U.S. TSCA assessments. Operationally, IFF is vulnerable to geopolitical instability and climate events affecting the sourcing of essential oils, vegetable oils, and botanicals. Furthermore, the company faces potential tax liabilities stemming from the N&B Reverse Morris Trust and evolving global frameworks like OECD Pillar Two. Cybersecurity threats and the integration of AI present additional risks to intellectual property and operational continuity, while the company continues to navigate a complex strategic transformation involving portfolio optimization and divestitures.

Source: SEC EDGAR filing text and events; period Feb 27, 2026; filed Feb 27, 2026.

Continue research

Keep researching IFF

Follow same-sector companies and source explainers connected to the research view.

Related tickers

NEM
Newmont
$105.66B
Materials
Open company page →
FCX
Freeport-McMoRan
$91.86B
Materials
Open company page →
SHW
Sherwin-Williams
$73.88B
Materials
Open company page →
ECL
Ecolab
$72.47B
Materials
Open company page →
CRH
CRH plc
$67.90B
Materials
Open company page →
APD
Air Products
$61.64B
Materials
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →